Survival outcomes in early-stage breast cancer are affected by length of the interval between diagnosis and surgery, with greater time to surgery associated with lower overall and disease-specific survival, according to 2 independent cohorts of 94,544 and 115,790 patients, respectively.
• In the SEER-Medicare cohort (patients aged ≥66 years), researchers found:
• Overall survival was lower with each interval of delay increase (HR, 1.09), and in patients with stage I (HR, 1.13) and stage II disease (HR 1.06).
• Breast cancer-specific mortality increased with each 60-day interval (subdistribution HR, 1.26).
• The National Cancer Database (NCDB) study (patients aged ≥18 years) found:
• Overall mortality HR was 1.10 for each increasing interval, significant in stages I (HR, 1.16) and II (HR, 1.09), after adjusting for demographic, tumor, and treatment factors.
Citation: Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. [Published online ahead of print December 10, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.4508.